Overview

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

A 48-week, open label, non comparative prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for more than 24 weeks (human immunodeficiency virus-1 RNA <50 c/ml) switching from an antiretroviral regimen containing tenofovir and lamivudine or emtricitabine and boosted protease inhibitor to boosted atazanavir and lamivudine Study visits will take place at screening, baseline, weeks 4, 12, 24, and 48.

Phase:

N/A

Details

Lead Sponsor:

David Garcia Cinca

Collaborators:

Fundacion Clinic per a la Recerca Biomédica
Jose Luis Blanco - Fundació Clínic per a la Recerca Biomèdica

Treatments:

Atazanavir Sulfate
Emtricitabine
HIV Protease Inhibitors
Lamivudine
Protease Inhibitors
Ritonavir
Tenofovir